KDR and neoplasm: Apatinib is a new type of small-molecule antiangiogenesis agent and a targeting tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2), thus suppressing tumor angiogenesis and being effective against tumors [9].